Potential in exosome-based targeted nano-drugs and delivery vehicles for posterior ocular disease treatment: from barriers to therapeutic application
- PMID: 37402019
- DOI: 10.1007/s11010-023-04798-w
Potential in exosome-based targeted nano-drugs and delivery vehicles for posterior ocular disease treatment: from barriers to therapeutic application
Abstract
Posterior ocular disease, a disease that accounts for 55% of all ocular diseases, can contribute to permanent vision loss if left without treatment. Due to the special structure of the eye, various obstacles make it difficult for drugs to reach lesions in the posterior ocular segment. Therefore, the development of highly permeable targeted drugs and delivery systems is particularly important. Exosomes are a class of extracellular vesicles at 30-150 nm, which are secreted by various cells, tissues, and body fluids. They carry various signaling molecules, thus endowing them with certain physiological functions. In this review, we describe the ocular barriers and the biogenesis, isolation, and engineering of exosomes, as exosomes not only have pharmacological effects but also are good nanocarriers with targeted properties. Moreover, their biocompatibility and immunogenicity are better than synthetic nanocarriers. Most importantly, they may have the ability to pass through the blood-eye barrier. Thus, they may be developed as both targeted nano-drugs and nano-delivery vehicles for the treatment of posterior ocular diseases. We focus on the current status and potential application of exosomes as targeted nano-drugs and nano-delivery vehicles in posterior ocular diseases.
Keywords: Exosome; Posterior ocular disease; Targeted nano-delivery vehicles; Targeted nano-drugs.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Nanocarrier-Based, ocular drug delivery: Challenges, prospects, and the therapeutic landscape in the United Arab Emirates.Int J Pharm. 2024 Dec 25;667(Pt B):124899. doi: 10.1016/j.ijpharm.2024.124899. Epub 2024 Nov 7. Int J Pharm. 2024. PMID: 39521159 Review.
-
Exosome: From biology to drug delivery.Drug Deliv Transl Res. 2024 Jun;14(6):1480-1516. doi: 10.1007/s13346-024-01515-y. Epub 2024 Jan 22. Drug Deliv Transl Res. 2024. PMID: 38252268 Review.
-
A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.J Drug Target. 2021 Aug;29(7):687-702. doi: 10.1080/1061186X.2021.1878366. Epub 2021 Feb 1. J Drug Target. 2021. PMID: 33474998 Review.
-
Targeted drug delivery vehicles mediated by nanocarriers and aptamers for posterior eye disease therapeutics: barriers, recent advances and potential opportunities.Nanotechnology. 2022 Jan 24;33(16). doi: 10.1088/1361-6528/ac46d5. Nanotechnology. 2022. PMID: 34965522 Review.
-
Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.ACS Nano. 2024 Aug 27;18(34):22793-22828. doi: 10.1021/acsnano.4c08486. Epub 2024 Aug 14. ACS Nano. 2024. PMID: 39141830 Free PMC article. Review.
Cited by
-
Research Advances of Engineered Exosomes as Drug Delivery Carrier.ACS Omega. 2023 Nov 9;8(46):43374-43387. doi: 10.1021/acsomega.3c04479. eCollection 2023 Nov 21. ACS Omega. 2023. PMID: 38027310 Free PMC article. Review.
-
Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes as Nanomedicine for Peripheral Nerve Injury.Int J Mol Sci. 2024 Jul 18;25(14):7882. doi: 10.3390/ijms25147882. Int J Mol Sci. 2024. PMID: 39063125 Free PMC article. Review.
-
Targeting the Ophthalmic Diseases Using Extracellular Vesicles 'Exosomes': Current Insights on Their Clinical Approval and Present Trials.Aging Dis. 2024 May 25;16(3):1225-1241. doi: 10.14336/AD.2024.0535. Aging Dis. 2024. PMID: 38913038 Free PMC article. Review.
-
Recent advances in engineered exosome-based therapies for ocular vascular disease.J Nanobiotechnology. 2025 Jul 19;23(1):526. doi: 10.1186/s12951-025-03589-3. J Nanobiotechnology. 2025. PMID: 40684186 Free PMC article. Review.
-
Harnessing the potential of mesenchymal stem cells-derived exosomes in degenerative diseases.Regen Ther. 2024 Aug 20;26:599-610. doi: 10.1016/j.reth.2024.08.001. eCollection 2024 Jun. Regen Ther. 2024. PMID: 39253597 Free PMC article. Review.
References
-
- Juliana FR, Kesse S, Boakye-Yiadom KO, Veroniaina H, Wang HH, Sun MH (2019) Promising approach in the treatment of glaucoma using nanotechnology and nanomedicine-based systems. Molecules. https://doi.org/10.3390/molecules24203805 - DOI - PubMed - PMC
-
- Joseph RR, Venkatraman SS (2017) Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine 12:683–702. https://doi.org/10.2217/nnm-2016-0379 - DOI - PubMed
-
- Nayak K, Misra M (2018) A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother 107:1564–1582. https://doi.org/10.1016/j.biopha.2018.08.138 - DOI - PubMed
-
- Wang R, Gao Y, Liu AC, Zhai GX (2021) A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances. J Drug Target 29:687–702. https://doi.org/10.1080/1061186x.2021.1878366 - DOI - PubMed
-
- Naidorf-Rosenblatt H, Landau-Part D, Moisseiev J, Alhalel A, Huna-Baron R, Skaat A, Pilus S, Levi L, Leshno A (2022) Ocular surface temperature differences in retinal vascular diseases. Retina-J Retinal Vitreous Dis 42:152–158. https://doi.org/10.1097/IAE.0000000000003278 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical